Empagliflozin in HNF1A-MODY (MODY3)—a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
Empagliflozin used for 4 weeks in adjunction with other glucose-lowering treatments markedly improved glycemia compared with placebo in individuals with HNF1A-MODY without significantly increasing risk of hypoglycemia or unexpected adverse effects.
Authors
- Henrik Maagensen (ORCID: https://orcid.org/0000-0002-0399-9898)
- Julie Lyng Forman (ORCID: https://orcid.org/0000-0001-7368-0869)
- TINA VILSBØLL
- Jan Skov Jensen (ORCID: https://orcid.org/0000-0001-9468-6100)
- Stine O. Høyerup
- Henrik Vestergaard
- Filip K. Knop
- Torben Hansen
- Anne C.B. Thuesen
- Sofie Hædersdal
- Julie Støy
- Henrik H. Thomsen
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Aarhus University (DK)
- Novo Nordisk Foundation (DK)
- Aarhus University Hospital (DK)
- Gentofte Hospital (DK)
- Regional Hospital Central Jutland (DK)
Publication Details
- Journal
- Diabetes Care
- Published
- 2026-01-12
- DOI
- https://doi.org/10.2337/dc25-2572
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00